Patrick Bilbo - Organogenesis Holdings Chief Officer
| ORGO Stock | USD 3.90 0.06 1.52% |
Insider
Patrick Bilbo is Chief Officer of Organogenesis Holdings
| Age | 62 |
| Address | 85 Dan Road, Canton, MA, United States, 02021 |
| Phone | 781 575 0775 |
| Web | https://organogenesis.com |
Patrick Bilbo Latest Insider Activity
Tracking and analyzing the buying and selling activities of Patrick Bilbo against Organogenesis Holdings stock is an integral part of due diligence when investing in Organogenesis Holdings. Patrick Bilbo insider activity provides valuable insight into whether Organogenesis Holdings is net buyers or sellers over its current business cycle. Note, Organogenesis Holdings insiders must abide by specific rules, including filing SEC forms every time they buy or sell Organogenesis Holdings'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Patrick Bilbo over six months ago Disposition of 152250 shares by Patrick Bilbo of Organogenesis Holdings at 1.18 subject to Rule 16b-3 |
Organogenesis Holdings Management Efficiency
The company has return on total asset (ROA) of 0.0164 % which means that it generated a profit of $0.0164 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0266) %, meaning that it created substantial loss on money invested by shareholders. Organogenesis Holdings' management efficiency ratios could be used to measure how well Organogenesis Holdings manages its routine affairs as well as how well it operates its assets and liabilities. As of the 28th of November 2024, Return On Tangible Assets is likely to grow to 0.01. Also, Return On Capital Employed is likely to grow to 0.03. At this time, Organogenesis Holdings' Return On Assets are very stable compared to the past year. As of the 28th of November 2024, Asset Turnover is likely to grow to 1.20, while Total Assets are likely to drop about 292.5 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Micha BenChorin | Redhill Biopharma | 55 | |
| Jude Onyia | Neurocrine Biosciences | 60 | |
| Justin Burgess | Dynavax Technologies | N/A | |
| Marlo Manning | Collegium Pharmaceutical | N/A | |
| Meg Smith | Dynavax Technologies | N/A | |
| Thomas Harvey | Alkermes Plc | N/A | |
| Floyd MD | Alkermes Plc | 87 | |
| Eiry MD | Neurocrine Biosciences | 60 | |
| Damon Terrill | Alpha Teknova | 53 | |
| Scott Sudduth | Collegium Pharmaceutical | N/A | |
| Mitchell MBA | Petros Pharmaceuticals | 60 | |
| Rob Jackson | Redhill Biopharma | N/A | |
| Kristin Comer | Redhill Biopharma | N/A | |
| Lisa McCann | Alpha Teknova | 42 | |
| Robert Weinstein | Petros Pharmaceuticals | 64 | |
| Matthew Lowell | Alpha Teknova | 54 | |
| Michael Starkweather | Shuttle Pharmaceuticals | 40 | |
| Keith Lavan | Petros Pharmaceuticals | 60 | |
| MSc MPhil | Redhill Biopharma | 49 | |
| Aaron Perlitsh | Lifecore Biomedical | N/A | |
| Richard MD | Collegium Pharmaceutical | 64 | |
Management Performance
| Return On Equity | -0.0266 | ||||
| Return On Asset | 0.0164 |
Organogenesis Holdings Leadership Team
Elected by the shareholders, the Organogenesis Holdings' board of directors comprises two types of representatives: Organogenesis Holdings inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Organogenesis. The board's role is to monitor Organogenesis Holdings' management team and ensure that shareholders' interests are well served. Organogenesis Holdings' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Organogenesis Holdings' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Gary Sr, CEO, President | ||
| BA Esq, VP Counsel | ||
| Patrick Bilbo, Chief Officer | ||
| Thomas Pearl, Vice Resources | ||
| Zorina Pitkin, VP Systems | ||
| Brian Grow, Chief Officer | ||
| Kurt Matheson, VP Marketing | ||
| David Francisco, Chief Officer | ||
| William CPA, Secretary | ||
| Robert Cavorsi, Vice Strategy |
Organogenesis Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Organogenesis Holdings a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0266 | ||||
| Return On Asset | 0.0164 | ||||
| Profit Margin | (0.02) % | ||||
| Operating Margin | 0.05 % | ||||
| Current Valuation | 538.33 M | ||||
| Shares Outstanding | 132.58 M | ||||
| Shares Owned By Insiders | 43.44 % | ||||
| Shares Owned By Institutions | 48.28 % | ||||
| Number Of Shares Shorted | 10.41 M | ||||
| Price To Earning | 17.12 X |
Pair Trading with Organogenesis Holdings
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Organogenesis Holdings position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Organogenesis Holdings will appreciate offsetting losses from the drop in the long position's value.Moving together with Organogenesis Stock
| 0.84 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
Moving against Organogenesis Stock
| 0.84 | PEPG | PepGen | PairCorr |
| 0.82 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
| 0.76 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.76 | NKTX | Nkarta Inc Buyout Trend | PairCorr |
| 0.73 | MREO | Mereo BioPharma Group | PairCorr |
The ability to find closely correlated positions to Organogenesis Holdings could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Organogenesis Holdings when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Organogenesis Holdings - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Organogenesis Holdings to buy it.
The correlation of Organogenesis Holdings is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Organogenesis Holdings moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Organogenesis Holdings moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Organogenesis Holdings can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Organogenesis Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in Organogenesis Stock, please use our How to Invest in Organogenesis Holdings guide.You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Organogenesis Holdings. If investors know Organogenesis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Organogenesis Holdings listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 3.5 | Earnings Share (0.05) | Revenue Per Share 3.446 | Quarterly Revenue Growth 0.061 | Return On Assets 0.0164 |
The market value of Organogenesis Holdings is measured differently than its book value, which is the value of Organogenesis that is recorded on the company's balance sheet. Investors also form their own opinion of Organogenesis Holdings' value that differs from its market value or its book value, called intrinsic value, which is Organogenesis Holdings' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Organogenesis Holdings' market value can be influenced by many factors that don't directly affect Organogenesis Holdings' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Organogenesis Holdings' value and its price as these two are different measures arrived at by different means. Investors typically determine if Organogenesis Holdings is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Organogenesis Holdings' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.